Patents by Inventor Joy Ku

Joy Ku has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Unified platform for rapid production of nanovaccines with enhanced safety, efficacy and precision
    Patent number: 12651648
    Abstract: A unified platform including an exosome-based method has been developed that uses only immunogenic epitopes for nanovaccine production. By eliminating these nonessential sequences from the full-length antigen, this new type of nanovaccine is safer as compared to those of existing vaccines. In addition, careful selection of targeting epitopes and incorporation of multiple epitope repeats into nanovaccine will make it more potent and precise than the traditional vaccines.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: June 9, 2026
    Assignee: Santa Clara University
    Inventors: Biao Lu, Joy Ku, Renceh Flojo, Christopher James Olson
  • Targeted degradation and removal of amyloid beta plaques for the prevention and treatment of alzheimer’s diseases via engineered nano-scavenger exosomes
    Publication number: 20250082775
    Abstract: Exosome-Based Nano-Scavenger (EBNS) are provided to precisely target and remove A? plaques. Leveraging exosomes, natural cell-derived vesicles with tissue-penetrating capabilities, these exosomes were engineered to carry disease targeting antibodies and A?-degrading enzymes, clearing A? specifically, safely and effectively. EBNS can overcome existing treatment limitations and offer a promising avenue for Alzheimer's Disease therapy.
    Type: Application
    Filed: June 6, 2024
    Publication date: March 13, 2025
    Inventors: Biao Lu, Renceh Flojo, Joy Ku
  • Unified platform for rapid production of nanovaccines with enhanced safety, efficacy and precision
    Publication number: 20240055079
    Abstract: A unified platform including an exosome-based method has been developed that uses only immunogenic epitopes for nanovaccine production. By eliminating these nonessential sequences from the full-length antigen, this new type of nanovaccine is safer as compared to those of existing vaccines. In addition, careful selection of targeting epitopes and incorporation of multiple epitope repeats into nanovaccine will make it more potent and precise than the traditional vaccines.
    Type: Application
    Filed: August 2, 2023
    Publication date: February 15, 2024
    Inventors: Biao Lu, Joy Ku, Renceh Flojo, Christopher James Olson